Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dynogen Pharmaceuticals, Inc.
Pharmaceutical company licenses compounds for GU and GI disorders
November 6th, 2004
Dynogen Pharmaceuticals, Inc., and Newron Pharmaceuticals S.p.A. announced the signing of a license agreement under which Dynogen has obtained exclusive rights to certain Newron compounds in order to explore their clinical potential for genitourinary (GU) and gastrointestinal (GI) disorders. Under the terms of the agreement, Newron granted Dynogen an exclusive, worldwide license to a number of ion channel modulators including extensive pre-clinical data packages and related intellectual property. Dynogen will apply its predictive pharmacology platform to identify those compounds that have the greatest potential for clinical efficacy in GU and GI...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2004-11-06)
|
